Cai et al., 2024 - Google Patents

Inhibiting endothelial cell‐mediated T lymphocyte apoptosis with integrin‐targeting peptide‐drug conjugate filaments for chemoimmunotherapy of triple‐negative …

Cai et al., 2024

Document ID
4444955035911998220
Author
Cai Y
Zhu B
Shan X
Zhou L
Sun X
Xia A
Wu B
Yu Y
Zhu H
Zhang P
Li Y
Publication year
Publication venue
Advanced Materials

External Links

Snippet

Tumor‐associated endothelial cells (TECs) limit antitumor immunity via inducing apoptosis of infiltrating T lymphocytes through a Fas ligand (FasL) mediated mechanism. Herein, this work creates a peptide‐drug conjugate (PDC) by linking 7‐ethyl‐10‐hydroxycamptothecin …
Continue reading at advanced.onlinelibrary.wiley.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48238—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid
    • A61K47/48246—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations

Similar Documents

Publication Publication Date Title
Cai et al. Inhibiting endothelial cell‐mediated T lymphocyte apoptosis with integrin‐targeting peptide‐drug conjugate filaments for chemoimmunotherapy of triple‐negative breast cancer
Zheng et al. Remodeling tumor immune microenvironment (TIME) for glioma therapy using multi-targeting liposomal codelivery
Cai et al. Photodynamic therapy combined with antihypoxic signaling and CpG adjuvant as an in situ tumor vaccine based on Metal–Organic framework nanoparticles to boost cancer immunotherapy
Kuang et al. iRGD modified chemo‐immunotherapeutic nanoparticles for enhanced immunotherapy against glioblastoma
Wang et al. Hybrid ginseng‐derived extracellular vesicles‐like particles with autologous tumor cell membrane for personalized vaccination to inhibit tumor recurrence and metastasis
Du et al. pH/Cathepsin B hierarchical‐responsive nanoconjugates for enhanced tumor penetration and chemo‐immunotherapy
Deng et al. Tumors and their microenvironment dual‐targeting chemotherapy with local immune adjuvant therapy for effective antitumor immunity against breast cancer
Li et al. A supramolecular “trident” for cancer immunotherapy
Liu et al. Ferritin‐based nanocomposite hydrogel promotes tumor penetration and enhances cancer chemoimmunotherapy
Xie et al. Hsp70‐targeting and size‐tunable nanoparticles combine with PD‐1 checkpoint blockade to treat glioma
Zhong et al. Plasma membrane targeted photodynamic nanoagonist to potentiate immune checkpoint blockade therapy by initiating tumor cell pyroptosis and depleting infiltrating B cells
Mamuti et al. A polyvalent peptide CD40 nanoagonist for targeted modulation of dendritic cells and amplified cancer immunotherapy
Zhang et al. In situ sting‐activating nanovaccination with tigit blockade for enhanced immunotherapy of anti‐Pd‐1‐resistant tumors
Chen et al. A Transformable Supramolecular Bispecific Cell Engager for Augmenting Natural Killer and T Cell‐Based Cancer Immunotherapy
Wang et al. Laser‐Activatable In Situ Vaccine Enhances Cancer‐Immunity Cycle
Huang et al. Current strategies for the treatment of hepatocellular carcinoma by modulating the tumor microenvironment via nano-delivery systems: a review
Wang et al. Genetically Engineered Hematopoietic Stem Cells Deliver TGF‐β Inhibitor to Enhance Bone Metastases Immunotherapy
Yi et al. Sequentially targeting cancer‐associated fibroblast and mitochondria alleviates tumor hypoxia and inhibits cancer metastasis by preventing “soil” formation and “seed” dissemination
Lu et al. An OMV‐Based Nanovaccine as Antigen Presentation Signal Enhancer for Cancer Immunotherapy
Dong et al. ZIF‐8‐Encapsulated Pexidartinib Delivery via Targeted Peptide‐Modified M1 Macrophages Attenuates MDSC‐Mediated Immunosuppression in Osteosarcoma
Shen et al. Sequential receptor–mediated mixed-charge nanomedicine to target pancreatic cancer, inducing immunogenic cell death and reshaping the tumor microenvironment
Lin et al. Self‐delivered transformable nanosystem capable of enhancing photodynamic effectiveness and multi‐target ameliorating immunosuppression for treatment of breast cancer and lung metastasis
Cao et al. Extracellular vesicles as drug vectors for precise cancer treatment
Miloradovic et al. The effects of mesenchymal stem cells on antimelanoma immunity depend on the timing of their administration
Jiang et al. Synergistic approach to combat triple‐negative breast cancer: B7‐H4 checkpoint‐based photodynamic nanodrug coupled with neutrophil extracellular trap regulation